Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
N
-acetylaspartate network begins in neurons with
N
-acetylaspartate production catalyzed by aspartate
N
-acetyltransferase from acetyl-CoA and aspartate. Clinical studies reported a significant depletion in
N
-acetylaspartate brain level in type 1 diabetic patients. The main goal of this study was to establish the impact of either hyperglycemia or oxidative stress on the
N
-acetylaspartate network. For the in vitro part of the study, embryonic rat primary neurons were treated by using a nitric oxide generator for 24 h followed by 6 days of post-treatment culture, while the neural stem cells were cultured in media with 25-75 mM glucose. For the in vivo part, male adult Wistar rats were injected with streptozotocin (65 mg/kg body weight, ip) to induce hyperglycemia (diabetes model) and euthanized 2 or 8 weeks later. Finally, the biochemical profile,
NAT8L
protein/
Nat8l
mRNA levels and enzymatic activity were analyzed. Ongoing oxidative stress processes significantly affected energy metabolism and cholinergic neurotransmission. However, the applied factors did not affect the
N
-acetylaspartate network. This study shows that reduced
N
-acetylaspartate level in
type 1 diabetes
is not related to oxidative stress and that does not trigger
N
-acetylaspartate network fragility. To reveal why
N
-acetylaspartate is reduced in this pathology, other processes should be considered.
...
PMID:Neither Excessive Nitric Oxide Accumulation nor Acute Hyperglycemia Affects the
N
-Acetylaspartate Network in Wistar Rat Brain Cells. 3319 75